Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).
Epistemonikos ID: ba44b858267f008e000a6ca61bbff24486f69466
First added on: Aug 27, 2026